IDENTIFYING AND TARGETING EPIGENETIC VULNERABILITIES IN THE HISTONE H3 LYSINE 36 METHYLATION AXIS IN RENAL CELL CANCER.
$918,822FY2021Defense Health AgencyDOD
Mayo Clinic, Rochester MN
Investigators
View source on USAspending →IDENTIFYING AND TARGETING EPIGENETIC VULNERABILITIES IN THE HISTONE H3 LYSINE 36 METHYLATION AXIS IN RENAL CELL CANCER. · GrantIndex